GRCL News and Press, Gracell Biotechnologies Inc. From 03/14/22

Gracell Biotechnologies press release (NASDAQ:GRCL): Q4 GAAP EPS of -$0.06 beats by $0.10. As of December 31, 2021, the Company had RMB1,832.6 million (US$287.6 million) in cash and cash equivalents and short-term investments. For further details see: Gracell Biotechnologies GAAP EPS of...

Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022 Allogeneic TruUCAR-T GC502 currently being investigated in a first-in-human investigator-initiated trial (IIT) in China in B-cell malignanci...

PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the t...

Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022 PR Newswire Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZ...

PALO ALTO, Calif. and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of canc...

Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform Abstract providing early first-in-human data on GC502 accepted for presentation at American Association for Cancer Research (AACR) Annual Meeting 2022 PR Newswire SUZHOU, C...

China's National Medical Products Administration approved Pfizer's Paxlovid, an oral COVID-19 therapy for adults who have mild-to-moderate COVID-19 and are at high risk of progressing to severe disease. The approval is conditional, based on Pfizer providing additional data. Shanghai S...

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma Candidate dual-targeting B cell maturation antigen (BCMA) and CD19 expands Gracell's FasTCAR autologous, next-d...

Gainers: Tritium DCFC DCFC +82%. US Ecology ECOL +69%. Moving iMage Technologies MITQ +29%. Solid Power (NASDAQ:SLDP) +23%. Kaival Brands Innovations Group (NASDAQ:KAVL) +23%. Doximity DOCS +23%. Gracell Biotechnologies (NASDAQ:GRCL) +20%. Bakkt Holdings (NYSE:BKKT) +20%. ...

SUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...